ArticleJournal of inflammation research2026
Formononetin Protects Against Cerebral Ischemia-Reperfusion-Induced Lung Injury: Insights from Animal and Cell Models.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral ischemia-reperfusion (CIR) affects multiple organs, with lung injury being particularly prevalent. Formononetin, derived from legumes, has multiple pharmacological effects and demonstrated potential for the treatment of neurological diseases. However, its effects on CIR-induced lung injury are unknown. Objective: To investigate the protective effect of formononetin in CIR-induced lung injury (in the Sprague-Dawley (SD) rats' model). Methods: Sprague-Dawley rats (n=27) underwent middle cerebral artery occlusion (MCAO) to establish a CIR model. Formononetin was then administered at specific time points. Longa neurological deficit score, histological staining, enzyme-linked immunosorbent assay (ELISA), and flow cytometry were subsequently used to assess lung injury. In addition, rat microglia were exposed to oxygen-glucose deprivation/re-oxygenation (OGD/R) to mimic CIR in vitro, and exosomes were then extracted from these cells for testing. A lipopolysaccharide (LPS)-induced lung epithelial cell injury model was subsequently used to investigate the protective effects of formononetin. Results: ELISA revealed that formononetin exerted broad-spectrum anti-inflammatory effects, reducing TNF-α, IL-1β, IL-6, and IL-10 by 46.7%, 46.2%, 40.1%, and 54.6%, respectively, in bronchoalveolar lavage fluid after MCAO (P<0.05). In lung tissues, superoxide dismutase (SOD) expression was increased, while malondialdehyde (MDA) was decreased (22.8%). Additionally, formononetin reduced interferon-gamma positive (INF-γ⁺), IL-4⁺, IL-17A⁺, forkhead box P3 protein positive (Foxp3⁺), cluster of differentiation 4 positive (CD4⁺), and CD8⁺ by 72.3%, 76.7%, 66.1%, 67.7%, 78.4%, and 80.4%, respectively, all to sham levels (P < 0.05). The in vitro experiments also revealed a downward trend in the expression of inflammatory factors in lung epithelial cells, with increased SOD expression (26.2%) and decreased MDA levels (21.7%, P<0.05). Conclusion: Formononetin protects against lung injury by inhibiting inflammatory cytokines, reducing oxidative stress, and regulating immune cells. Notably, exosomes derived from formononetin-treated microglia were shown to attenuate LPS-induced lung epithelial cell injury, highlighting a novel intercellular communication pathway. Together, these in vivo and in vitro studies offer new insights into the clinical application of formononetin in cerebrovascular diseases for secondary lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.